Epigenetic?s Researcher?s Enthuse Over ChromaTrap ChIP Technology
Porvair Sciences reports strong growing demand for their Chromatrap chromatin immunoprecipitation (ChIP) assay technology from academic groups and biopharmaceutical organisations involved with epigenetic research.
Stephen Knight, Sales and Marketing Director commented: "An expanding number of proven application solutions and the introduction of the Chromatrap 96 HT solid-state ChIP high throughput platform has enabled us to more than double the number of research groups using ChromaTrap assay technology during the last 12 months." He added: "We are particularly pleased by the very positive feedback from early adopters of the technology."
Brian J. Engel, a Biochemistry & Cell Biology researcher at Rice University, USA commented: "What I like most about the Chromatrap kit compared with traditional bead-based ChIP assays is the ease of use, speed and reliability. There is no worry about accidentally losing beads during washes and reducing output chromatin when using the column-based method." His colleague, Curt Warren, added: "We have found that the Chromatrap kit is quick, reliable and flexible. Saving reagents and time with this kit makes it easier and more feasible to conduct more thorough and effective IP-based experiments. With the enhanced reproducibility using Chromatrap, I would not go back to bead-based ChIP and the assay has been fully endorsed and adopted within our research team."
Professor Steve Conlan, Head of Molecular & Cell Biology at Swansea University, UK commented: "Chromatrap streamlines the complicated experimental procedure associated with chromatin-IP making it a much quicker and user-friendly assay compared with conventional bead based assays. Using this kit we obtain much more consistent data, and most importantly can use much less input sample. We have made a permanent switch to using Chromatrap for all our cell line and primary cell based assays, and fully endorse the technology." Research assistant, Dr Helen Whiteland, added: "What I like about the Chromatrap assay is the ease of use and quick method allowing me to analyse my data in the same day."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance